The total private drug plan (PDP) drug cost is expected to grow at a compound annual rate (CAGR) of 4.66 per cent from 2017 to 2019, the forecast impacted by utilization (3.8 per cent), recent new drug entries (2.02 per cent), and specialty drugs (2.14 per cent)